HC
QNCX icon

Hurley Capital’s Quince Therapeutics QNCX Stock Holding History

Hurley Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12 Hold
1
– – ﹤0.01% 663
2025
Q4 		$405 Hold
1
– – ﹤0.01% 550
2025
Q3 		$197 Hold
1
– – ﹤0.01% 656
2025
Q2 		$200 Hold
1
– – ﹤0.01% 441
2025
Q1 		$161 Hold
1
– – ﹤0.01% 479
2024
Q4 		$236 Buy
+1
New +$300 ﹤0.01% 386

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hurley Capital's QNCX Position: Q1 2026 in Review

Hurley Capital held its Quince Therapeutics (QNCX) position steady in Q1 2026 at 1 share worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Hurley Capital first reported a position in QNCX in Q4 2024 and has held it in 6 quarters since. The position peaked at $405 in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Hurley Capital held 1 share of Quince Therapeutics worth $12 as of Q1 2026.
  • Hurley Capital left its Quince Therapeutics share count unchanged in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #663 holding.
  • Hurley Capital first reported a position in Quince Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Hurley Capital's Quince Therapeutics position peaked at $405 in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.